Public record
GHK-Cu: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Product listings
FDA product listings naming GHK-Cu
The FDA NDC Directory holds 10 listings naming GHK-Cu from 8 firms: 8 bulk ingredient listings and 2 finished product listings, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming GHK-Cu | 10 | |
| Bulk ingredient listings | 8 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 1 | |
| Finished product listings | 2 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 8 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains GHK-Cu or GHK copper or copper tripeptide-1
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
Clinical studies
Registered clinical studies of GHK-Cu
ClinicalTrials.gov lists 4 registered studies that name GHK-Cu as an intervention as of 2026-11-11. Of these, 1 are recruiting, 1 are completed and 0 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 4 |
| Recruiting now | 1 |
| Not yet recruiting | 1 |
| Completed | 1 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 0 |
| Phase 2 (including phase 1/2) | 1 |
| Phase 1 | 1 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches GHK-Cu or GHK copper or copper tripeptide-1, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
Published research
Published papers mentioning GHK-Cu
PubMed indexes 93 papers that mention GHK-Cu in the title or abstract, 55 of them published from 2016 to 2025. The count for 2025 is 9 and for 2024 is 8.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 93 | |
| Published 2016 to 2025 | 55 | |
| Published in 2025 | 9 | |
| Published in 2024 | 8 | |
| Busiest year since 2016 | 2023 | 13 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'GHK-Cu' or 'GHK copper' or 'copper tripeptide-1' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
Articles on GHK-Cu
- GHK-Cu Adult (30-49) Monitoring: What to Track and When
- GHK-Cu for Post-Surgical Recovery: Evidence, Dosing, and Clinical Use
- GHK-Cu History and Development: From Discovery to Modern Peptide Therapy
- GHK-Cu Metabolism and Energy Expenditure: What the Evidence Actually Shows
- GHK-Cu Pharmacogenomics & Genetic Variability: How Your Genes Shape Copper Peptide Response
- GHK-Cu Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion